<DOC>
	<DOCNO>NCT00357916</DOCNO>
	<brief_summary>To determine sensitisation potential PEP005 Topical Gel ( 0.01 % concentration ) normal skin To evaluate skin irritation</brief_summary>
	<brief_title>Study Determine Sensitizing Potential PEP005 Topical Gel Healthy Volunteers Using Repeat Insult Patch Test Design</brief_title>
	<detailed_description>This repeat insult patch test study . On treatment day , investigational product PEP005 Topical Gel ( 0.01 % concentration ) vehicle control apply open condition sit infrascapular region back 3 time weekly 3 week ( 9 application total ) induction phase . Following rest period approximatley 10-14 day , single challenge application perform . Local tolerability assess visually use ordinal scoring system . If cutaneous response observe challenge phase indicate possible sensitisation , discretion investigator , rechallenge occur</detailed_description>
	<criteria>1. healthy male female ( confirm medical history ) ; 2. 18 65 year age ; 3. Fitzpatick skin type I , II , III , IV 4. willing wait 6 hour product application shower ; 5. case female childbearing potential , use acceptable form birth control ( oral/implant/injectable/transdermal contraceptive , intrauterine device , condom spermicide , diaphragm , abstinence ) , negative urine pregnancy test Screening , submit pregnancy test prior challenge application ; 6. free systemic dermatologic disorder , , opinion investigator , interfere study result increase risk adverse event ; 7. acceptable vital sign ( ie oral body temperature , blood pressure ( systolic diastolic ) , pulse rate ) take willing take end study ( EOS , within 7 day initial challenge evaluation ) ; 8. complete medical screening procedure ; 9. read , understand provide sign informed consent . 1. visible skin disease application site , opinion investigative personnel , interfere evaluation test site reaction ; 2. Fitzpatrick skin type V VI ; 3. excessive hair back ; 4. current drug alcohol abuse ; 5. clinically significant illness may influence outcome study within 4 week prior study ; 6. willing refrain use topical/systemic analgesic aspirin , Aleve , Motrin , Advil , Nuprin within 72 hour prior study ( occasional use Tylenol permit ) ; 7. base investigator 's initial examination participate study ( ie , non compliance , inability understand study give adequate inform consent ) 8. use systemic/locallyacting medication might counter influence study aim study within 2 week prior begin study ( eg , antihistamine , topical glucocorticosteroids ) ; 9. use systemic/locallyacting antiinflammitories might counter influence study aim study within 72 hour prior begin study ; 10. female pregnant , plan become pregnant study , nurse child ; 11. know sensitivity allergy constituent present material evaluate ; and/or 12. participated clinical test investigational drug within 28days clinical patch study within 14days prior currently participate clinical testing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PEP005</keyword>
	<keyword>Safety</keyword>
</DOC>